Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30606520 | 0.98 | CSNK1E (0.39) | CSNK1ESPHK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31287490 | 0.84 | ALOX5 (0.44) | PPARG | |
| SCHEMBL21423075 | 0.83 | MEN1 (0.41) | CSNK1ESPHK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23564615 | 0.81 | MEN1 (0.40) | CSNK1ESPHK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20833289 | 0.81 | CES2 (0.40) | CES2CES1 | |
| SCHEMBL4290441 | 0.81 | PPARG (0.42) | CSNK1ESPHK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8746416 | 0.81 | PPARG (0.42) | CSNK1ESPHK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4825249 | 0.81 | PPARG (0.42) | CSNK1ESPHK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7523840 | 0.81 | PPARG (0.42) | CSNK1ESPHK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL26326736 | 0.80 | CSNK1E (0.42) | CSNK1EPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271988-A1 | METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271988-A1 | METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE | HPD, TALDO1, OGG1 | CSNK1E 4154/4885SPHK1 3549/4885MEN1 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.